Successful in vaccines, scientists turn mRNA into autoimmune diseases

What is it?

STAT + is STAT’s premium subscription service for coverage and in-depth analysis of biotechnology, pharmaceutical industry, politics and life sciences. Our award-winning team covers news on Wall Street, policy developments in Washington, initial scientific discoveries and clinical trial results, as well as health interruptions in Silicon Valley and beyond.

What’s included?

• Daily reports and analysis
• The most comprehensive coverage in the industry by a powerful team of reporters
• Subscriber-only newsletters
• Daily newsletters to inform you of the most important news in the sector on the day
• STAT + conversations
• Weekly opportunities to interact with our reporters and industry-leading experts in live video chats
• Exclusive industry events
• Premium access to network events only for subscribers across the country
• The best reporters in the industry
• The most trusted and well-connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.